Conditionally replicating adenoviruses carrying mda-7/IL-24 for cancer therapy

References

• Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 1996;93: 9160–5.
   PubMed Web of Science ®Google Scholar
• Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, . mda-7/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol 2007;31:985–1007.
   PubMed Web of Science ®Google Scholar
• Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, . Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther 2009;8:391–400.
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, . The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther 2010;128:375–84.
   PubMedGoogle Scholar
• Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L, . mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 2006;111:596–628.
   PubMed Web of Science ®Google Scholar
• Eager R, Harle L, Nemunaitis J. Ad-MDA-7; INGN 241: A review of preclinical and clinical experience. Expert Opin Biol Ther 2008;8:1633–43.
   PubMed Web of Science ®Google Scholar
• Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, . Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: A phase I study. Mol Ther 2005;11:149–59.
   PubMed Web of Science ®Google Scholar
• Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006;2:137–43.
   PubMedGoogle Scholar
• Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009;16:473–88.
   PubMed Web of Science ®Google Scholar
• Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001;7:781–7.
   PubMed Web of Science ®Google Scholar
• Liu XY. Targeting gene-virotherapy of cancer and its prosperity. Cell Res 2006;16:879–86.
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, . An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274: 373–6.
   PubMed Web of Science ®Google Scholar
• Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, . An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134–9.
   PubMed Web of Science ®Google Scholar
• Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999;73:5333–44.
   PubMed Web of Science ®Google Scholar
• Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, . Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 2002;62:764–72.
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559–63.
   PubMed Web of Science ®Google Scholar
• Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, . Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61:517–25.
   PubMed Web of Science ®Google Scholar
• Breyer B, Jiang W, Cheng H, Zhou L, Paul R, Feng T, . Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther 2001;1:149–62.
   PubMedGoogle Scholar
• Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, . Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 2004;11:1694–702.
   PubMedGoogle Scholar
• Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, . Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003;8:449–58.
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, . a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879–85.
   PubMed Web of Science ®Google Scholar
• Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, Sohn JH, . Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene Ther 2006;17:379–90.
   PubMedGoogle Scholar
• Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995;11: 2477–86.
   PubMed Web of Science ®Google Scholar
• Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Ann Rev Immunol 2004;22:929–79.
   PubMed Web of Science ®Google Scholar
• Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, . Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 2001;20:7051–63.
   PubMed Web of Science ®Google Scholar
• Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001;167:3545–9.
   PubMed Web of Science ®Google Scholar
• Wang M, Tan Z, Zhang R, Kotenko SV, Liang P. Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem 2002;277:7341–7.
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, . Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002;277:47517–23.
   PubMed Web of Science ®Google Scholar
• Margue C, Kreis S. IL-24: Physiological and supraphysiological effects on normal and malignant cells. Curr Med Chem 2010;17:3318–26.
   PubMed Web of Science ®Google Scholar
• Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M, . mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: Correlation with expression of bcl-2 family members. Cancer Gene Ther 2006;13:490–502.
   PubMed Web of Science ®Google Scholar
• Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, . Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): Biologic outcome in advanced cancer patients. Mol Ther 2005;11: 160–72.
   PubMed Web of Science ®Google Scholar
• Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci U S A 2005;102:14034–9.
   PubMed Web of Science ®Google Scholar
• Sarkar D, Su ZZ, Fisher PB. Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): Efficacious reagents for cancer gene therapy. Cell Cycle 2006;5:1531–6.
   PubMed Web of Science ®Google Scholar
• Sarkar D, Su ZZ, Park ES, Vozhilla N, Dent P, Curiel DT, . A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Ther 2008;15: 293–302.
   PubMed Web of Science ®Google Scholar
• Sarkar D, Lebedeva IV, Su ZZ, Park ES, Chatman L, Vozhilla N, . Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res 2007;67: 5434–42.
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, . An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003;13: 481–9.
   PubMed Web of Science ®Google Scholar
• Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, . Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005;16:845–58.
   PubMed Web of Science ®Google Scholar
• Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, . Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 2008;22:361–9.
   PubMed Web of Science ®Google Scholar
• Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W, . The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006;13:1011–22.
   PubMed Web of Science ®Google Scholar
• Hu Z, Robbins JS, Pister A, Zafar MB, Zhang ZW, Gupta J, . A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy. Cancer Gene Ther 2009;17:235–43.
   PubMedGoogle Scholar
• Yu de B, Zhong SY, Yang M, Wang YG, Qian QJ, Zheng S, . Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer. Cancer Sci 2009;100:678–83.
   PubMedGoogle Scholar
• Wei N, Fan JK, Gu JF, He LF, Tang WH, Cao X, . A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy. Biochem Biophys Res Commun 2009;388:234–9.
   PubMedGoogle Scholar
• Wei N, Fan JK, Gu JF, Liu XY. Double-regulated oncolytic adenovirus-mediated interleukin-24 overexpression exhibits potent antitumor activity on gastric adenocarcinoma. Hum Gene Ther 2010;21:855–64.
   PubMedGoogle Scholar
• Hildeman DA, Mitchell T, Aronow B, Wojciechowski S, Kappler J, Marrack P. Control of Bcl-2 expression by reactive oxygen species. Proc Natl Acad Sci U S A 2003;100:15035–40.
   PubMed Web of Science ®Google Scholar
• Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, . A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008;389:1–6.
   PubMed Web of Science ®Google Scholar
• Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Bussemakers MJ. Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 2000;275:37496–503.
   PubMedGoogle Scholar
• Fan JK, Wei N, Ding M, Gu JF, Liu XR, Li BH, . Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene. Int J Cancer 2010;127:707–17.
   PubMed Web of Science ®Google Scholar
• Li B, Liu X, Fan J, Qi R, Bo L, Gu J, . A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. J Gene Med 2006;8:1232–42.
   PubMedGoogle Scholar
• Kamizono J, Nagano S, Murofushi Y, Komiya S, Fujiwara H, Matsuishi T, . Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Res 2005;65:5284–91.
   PubMed Web of Science ®Google Scholar
• Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM, . Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus. Hum Gene Ther 2009;20:818–30.
   PubMed Web of Science ®Google Scholar
• Xiao LL, Wu YM, Qian J, Tan Y, Xie GL, Zhang KJ, . The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus. Cancer Biol Ther 2010;10: 242–50.
   PubMedGoogle Scholar
• Carette JE, Graat HC, Schagen FH, Abou El Hassan MA, Gerritsen WR, van Beusechem VW. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J Gene Med 2005;7:1053–62.
   PubMed Web of Science ®Google Scholar
• Jin F, Kretschmer PJ, Hermiston TW. Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol Ther 2005;12:1052–63.
   PubMed Web of Science ®Google Scholar
• Young CS. The structure and function of the adenovirus major late promoter. Curr Top Microbiol Immunol 2003; 272:213–49.
   PubMedGoogle Scholar
• Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. Curr Top Microbiol Immunol 1995;199: 237–74.
   PubMedGoogle Scholar
• Luo J, Xia Q, Zhang R, Lv C, Zhang W, Wang Y, . Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin Cancer Res 2008;14:2450–7.
   PubMed Web of Science ®Google Scholar
• Jiang G, Liu YQ, Wei ZP, Pei DS, Mao LJ, Zheng JN. Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazine against melanoma cells via induction of apoptosis. Cancer Lett 2010;294:220–8.
   PubMedGoogle Scholar
• Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu XY. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncol 2010;49:91–9.
   PubMed Web of Science ®Google Scholar
• Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, . Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol Sin 2009;30:467–77.
   PubMed Web of Science ®Google Scholar
• Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, . A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11: 37–51.
   PubMed Web of Science ®Google Scholar
• Xiao L, Li X, Niu N, Qian J, Xie G, Wang Y. Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. Mol Cell Biochem 2010;340:31–40.
   PubMed Web of Science ®Google Scholar
• Yang C, Tong Y, Ni W, Liu J, Xu W, Li L, . Inhibition of autophagy induced by overexpression of mda-7/interleukin-24 strongly augments the antileukemia activity in vitro and in vivo. Cancer Gene Ther 2010;17:109–19.
   PubMed Web of Science ®Google Scholar
• Lopes MB. Angiogenesis in brain tumors. Microsc Res Tech 2003;60:225–30.
   PubMed Web of Science ®Google Scholar
• de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989–91.
   PubMed Web of Science ®Google Scholar
• Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, . High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835–46.
   PubMed Web of Science ®Google Scholar
• Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, . Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519–24.
   PubMed Web of Science ®Google Scholar
• Nicklin SA, Dishart KL, Buening H, Reynolds PN, Hallek M, Nemerow GR, . Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Lett 2003;201:165–73.
   PubMedGoogle Scholar
• Work LM, Ritchie N, Nicklin SA, Reynolds PN, Baker AH. Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. Gene Ther 2004;11:1296–300.
   PubMedGoogle Scholar
• Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, . CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther 2009;16:794–805.
   PubMed Web of Science ®Google Scholar
• Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004;10:5299–312.
   PubMedGoogle Scholar
• Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 2005;65:6882–90.
   PubMed Web of Science ®Google Scholar
• Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007;7:141–8.
   PubMed Web of Science ®Google Scholar
• Jiang G, Wei ZP, Pei DS, Xin Y, Liu YQ, Zheng JN. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. Biochem Biophys Res Commun 2011;406:311–4.
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000;74:2567–83.
   PubMed Web of Science ®Google Scholar
• Rebel VI, Hartnett S, Denham J, Chan M, Finberg R, Sieff CA. Maturation and lineage-specific expression of the coxsackie and adenovirus receptor in hematopoietic cells. Stem Cells 2000;18:176–82.
   PubMed Web of Science ®Google Scholar
• Jin J, Liu H, Yang C, Li G, Liu X, Qian Q, . Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: In vitro and in vivo evaluation. Mol Cancer Ther 2009;8:1387–97.
   PubMed Web of Science ®Google Scholar
• Wang G, Li G, Liu H, Yang C, Yang X, Jin J, . E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J Gene Med 2009;11:477–85.
   PubMed Web of Science ®Google Scholar
• Dhar D, Spencer JF, Toth K, Wold WS. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 2009;83:2130–9.
   PubMed Web of Science ®Google Scholar
• Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, . Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007;15:114–22.
   PubMed Web of Science ®Google Scholar
• Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, . Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007;15: 123–30.
   PubMed Web of Science ®Google Scholar
• Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D, . E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther 2008;15:40–50.
   PubMedGoogle Scholar
• Di Paolo NC, Tuve S, Ni S, Hellstrom KE, Hellstrom I, Lieber A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res 2006;66:960–9.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010;18: 243–50.
   PubMed Web of Science ®Google Scholar
• Steel JC, Morrison BJ, Mannan P, Abu-Asab MS, Wildner O, Miles BK, . Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus. Virology 2007;369:131–42.
   PubMed Web of Science ®Google Scholar
• Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, . Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006;66:1270–6.
   PubMed Web of Science ®Google Scholar
• Wildner O, Hoffmann D, Jogler C, Uberla K. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther 2003;10:791–802.
   PubMed Web of Science ®Google Scholar